IQVIA Holdings Inc (IQV)vsMainz Biomed BV (MYNZ)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
MYNZ
Mainz Biomed BV
$0.50
+0.16%
HEALTHCARE · Cap: $7.90M
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 2471337% more annual revenue ($16.31B vs $659,940). IQV leads profitability with a 8.3% profit margin vs 0.0%. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
MYNZ
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Intrinsic value data unavailable for MYNZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Reasonable price relative to book value
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : MYNZ
The strongest argument for MYNZ centers on Price/Book.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : MYNZ
The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
IQV carries more volatility with a beta of 1.41 — expect wider price swings.
IQV is growing revenue faster at 10.3% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IQV scores higher overall (72/100 vs 18/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Mainz Biomed BV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?